Article Text

Download PDFPDF

Response to: ‘Hydroxychloroquine shortages during the COVID-19 pandemic’ by Mendel et al
  1. Iain McInnes
  1. Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8QQ, UK
  1. Correspondence to Professor Iain McInnes, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8QQ, UK; iain.mcinnes{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

As the COVID-19 crisis moves to its next phase, from ‘acute to chronic’ as it were, it is important to note that a variety of immune modifier medicines are now being proposed or actively trialled in pursuit of a novel effective intervention for early through to poor prognosis coronavirus infection. Such imaginative and creative approaches are to be welcomed. Given the current mathematical models of COVID-19 pandemic resolution, it seems that this may be a lengthy scenario. In the meantime, some disease-modifying antirheumatic drugs (DMARD) are being used on a presumptive basis, for understandable compassionate reasons, though not always based on robust medical evidence. One consequence of widespread uptake of DMARD use in COVID-19 is that drug availability may be diminished and thereby hamper the management of existing immune-mediated inflammatory diseases and particularly rheumatic and musculoskeletal diseases (RMDs). Many people with RMDs are reliant on such DMARDs to retain their well-being and loss of therapeutics may lead potentially to flare, and disease progression. Mendel et al provide us with important evidence of hydroxychloroquine shortages in Canada provided via a survey of Canadian rheumatologists.1 They are to be commended for seeking evidence of the same. This aligns well with numerous similar reports emerging across European countries. The European League Against Rheumatism is committed to ensuring equitable access to the medicines necessary to optimally treat RMDs during the COVID-19 pandemic.2 This is especially the case when as yet, few or no randomised controlled data support the use of immune modifiers in the management of COVID-19. Thus, while we are supportive of high-quality clinical trial medicine and indeed are hopeful that successful outcomes will emerge in pursuit of a solution for COVID-19, we prefer that the use of agents such as hydroxychloroquine is reserved in the context of appropriate trials, be they of controlled or well-annotated cohort design.



  • Handling editor Josef S Smolen

  • Contributors Wrote letter.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Correspondence
    Arielle Mendel Sasha Bernatsky J Carter Thorne Diane Lacaille Sindhu R Johnson Évelyne Vinet